Kineticos invests in early-stage companies developing differentiated and novel therapeutics to fight antimicrobial resistance (AMR), including novel antibiotics, antifungals, and vaccines, as well as diagnostics and services.
Target companies have breakthrough technologies and a clear disease target with commercial potential. As your partner, we support business growth, team development, and strategy alignment.
The Kineticos AMR Accelerator (KAMRA) Fund is led by a team of scientists, operators, and investors with deep expertise in infectious diseases and drug development. With decades of combined experience, we work hands-on with early-stage companies to accelerate groundbreaking solutions in the fight against antimicrobial resistance.
Learn More
Kineticos is seeking to invest in therapeutic and enabling companies utilizing disruptive technologies such as diagnostics, novel antimicrobial and antifungal technologies, and other approaches to address the growing burden of AMR.
Learn More)
"As a dedicated champion for innovation and operational excellence, Kineticos brings a like-minded sense of urgency and purpose to our mission, and we are confident they will propel our efforts as we work to address critical unmet needs in chronic respiratory disease."Clarametyx | David Richards | CEO
){kind=logo}
Kineticos Launches Kinvard Bio to Advance Next-Generation Antibiotics in the Fight Against Antimicrobial Resistance Raleigh, North Carolina – February 24,…
){kind=logo}
Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund COLUMBUS, Ohio – January 28, 2025 – Clarametyx Biosciences Inc. (“Clarametyx”), a clinical…
)
Endolytix Closed on Additional Financing with New Investment from the Kineticos AMR Accelerator Fund I October 29, 2024 – Kineticos…